Mehmet Kemal Samur

Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma.

Ruiz-Heredia Y, Ortiz-Ruiz A, Samur MK, Garrido V, Rufian L, Sanchez R, Aguilar-Garrido P, Barrio S, Martín MA, Bolli N, Tai YT, Szalat R, Fulciniti M, Munshi N, Martínez-López J, Linares M, Gallardo M.

Cancers (Basel). 2021 Jun 25. 13(13). PMID: 34202390

ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment.

Liu J, Hideshima T, Xing L, Wang S, Zhou W, Samur MK, Sewastianik T, Ogiya D, An G, Gao S, Yang L, Ji T, Bianchi G, Wen K, Tai YT, Munshi N, Richardson P, Carrasco R, Cang Y, Anderson KC.

Sci Adv. 2021 Jun. 7(23). PMID: 34088671

Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma.

Kumar S, Buon L, Talluri S, Roncador M, Liao C, Zhao J, Shi J, Chakraborty C, Gonzalez G, Tai YT, Prabhala R, Samur MK, Munshi NC, Shammas MA.

Commun Biol. 2021 May 24. 4(1):617. PMID: 34031527

Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.

Ohguchi H, Park PMC, Wang T, Gryder BE, Ogiya D, Kurata K, Zhang X, Li D, Pei C, Masuda T, Johansson C, Wimalasena VK, Kim Y, Hino S, Usuki S, Kawano Y, Samur MK, Tai YT, Munshi NC, Matsuoka M, Ohtsuki S, Nakao M, Minami T, Lauberth S, Khan J, Oppermann U, Durbin AD, Anderson KC, Hideshima T, Qi J.

Blood Cancer Discov. 2021 07. 2(4):370-387. PMID: 34258103

miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.

Sewastianik T, Straubhaar JR, Zhao JJ, Samur MK, Adler K, Tanton HE, Shanmugam V, Nadeem O, Dennis PS, Pillai V, Wang J, Jiang M, Lin J, Huang Y, Brooks D, Bouxsein M, Dorfman DM, Pinkus GS, Robbiani DF, Ghobrial IM, Budnik B, Jarolim P, Munshi NC, Anderson KC, Carrasco RD.

Blood. 2021 Apr 08. 137(14):1905-1919. PMID: 33751108

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.

Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC.

Nat Commun. 2021 02 08. 12(1):868. PMID: 33558511

Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13.

Song Y, Du T, Ray A, Chauhan K, Samur M, Munshi N, Chauhan D, Anderson KC.

Blood Cancer J. 2021 01 13. 11(1):13. PMID: 33441535

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.

Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, Hungria V, Engelhardt M, Gay F, García Feria A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum C, Kumar S, Stadtmauer EA, Einsele H, Beksac M, Weisel K, Anderson KC, Mateos MV, Moreau P, San-Miguel J, Munshi NC, Avet-Loiseau H.

Blood. 2020 12 24. 136(26):3033-3040. PMID: 33367546

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.

Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, Dimopoulos M, Kulakova M, Lam A, Hashim M, He J, Heeg B, Ukropec J, Vermeulen J, Cote S, Bahlis N.

Blood Adv. 2020 12 08. 4(23):5988-5999. PMID: 33284948

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.

Ogiya D, Liu J, Ohguchi H, Kurata K, Samur MK, Tai YT, Adamia S, Ando K, Hideshima T, Anderson KC.

Blood. 2020 11 12. 136(20):2334-2345. PMID: 32844992